• Founded: 2010
  • Location: San Carlos, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin1b (stopped Aug 2023)
  • Therapy area: Oncology
  • Drug types: ONC, INF
  • Lead product: ATRC-101
  • Product link:
  • Funding: $125M IPO Jun 2019; $125M Sep 2018; $35M B Aug 2017; $56M A Nov 2015

job board

Short description:

Proprietary human antibody discovery platform

Drug notes:

ARTC-501/MAM01 Clin0 malaria; APN-497444 RD oncology; APN-346958 RD oncology; APN-122597 RD oncology

Long description:

Atreca is developing technology to predict and produce therapeutic antibodies against specific antigens. Using their proprietary Immune Repertoire Capture® technology, Atreca identifies functional human antibodies from patients who have an anti-tumor immune response. The technology enables Atreca to accurately quantitate and analyze a patient's antibody repertoire using bioinformatics expertise and select antibody sequences that led to the anti-tumor response. Following selection, Atreca uses their industrialized wet lab infrastructure to interrogate the clinical candidate antibodies that selectively bind tumor tissue. Atreca is building a diverse portfolio to drive tumor-targeting in multiple indications.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy